Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of RA and meeting the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA.~* Patients between the ages of 18 and 64 years, inclusive, at the Screening Visit.~* Female patient must be not pregnant, not breast feeding and one of the following conditions need to apply:~  1. Of non-childbearing potential based on documented surgical treatment or post-menopausal, meaning patient had spontaneous amenorrhea for at least 12 months without alternate medical cause prior to Screening Visit and follicle stimulating hormone (FSH) \> 40 U/mL at the Screening Visit.~ 2. Of childbearing potential and using a highly effective method of contraception and agrees to remain on a highly effective method from the time of signing the informed consent form (ICF) until 21 days after the last dose.~* Male patient must agree to stay abstinent or must use together with his female partner(s) a form of highly effective contraceptive (failure rate of \< 1% per year) from the time of signing the ICF until up to 3 months after the last dose of the study drug.~* Nonsmokers (or other nicotine use) as determined by history and by negative urine cotinine concentration at the Screening Visit and at Admission.~* Body mass index (BMI) between 18.5 and 32.0 kg/m2, inclusive, at the Screening Visit.~* Patient is required to have completed a COVID-19 vaccine regimen within no more than 5 months prior to screening to be eligible for the study.~* Permitted concomitant medications for any reason, must be on a stable dose.~* Permitted medications include: anti-malarials; nonsteroidal anti-inflammatory drugs including selective cyclooxygenase-2 inhibitors at approved dosage, and low dose oral corticosteroids; methotrexate concomitantly with folic acid or folinic acid.~Exclusion Criteria:~* Female patients who are breastfeeding or have a positive urine pregnancy test.~* Patients who are unable to eat the prescribed meals during the stay at the site; vegetarian or vegan.~* Patient has a history of significant drug allergy.~* Patient has used a study drug, any prohibited medication(s), over-the-counter (OTC) medications, vitamins, dietary and herbal supplements.~* Patient has a history of active suicidal ideation, or any psychiatric disorders that will affect the patient's ability to participate in the study.~* Patient has a current or recent history of uncontrolled, clinically significant infectious, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.~* Patient with any of the laboratory abnormalities as per reference.~* Patient has a history of alcohol and/or drug abuse within 24 weeks.~* Patient has positive results for drug testing and breath alcohol test.~* Regular consumption of alcohol within 6 months prior to the Screening Visit.~* Patient has positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis B core (HBc) antibodies, hepatitis C virus (HCV) antibody, and/or human immunodeficiency virus (HIV) antibody at Screening Visit.~* Patient has QT interval corrected for heart rate (QTc) using Fridericia's correction (QTcF) \> 450 ms for males or QTcF \> 470 ms for females either at the Screening Visit or Admission, based on safety 12-lead electrocardiogram (ECG). Patient has Screening or Admission ECG with second- or third-degree atrioventricular block, bundle branch block, arrhythmia (but not sinus arrhythmia or supraventricular premature beats), or illegible QT interval.~* Patient has history or evidence of cardiopathy, acute coronary syndrome, hypertrophic cardiomyopathy, myocarditis or QT prolongation syndrome.~* Patient is unwilling to abstain from drinks and foods containing alcohol, grapefruit, or caffeine~* Patient has donated blood or experienced acute blood loss (including plasmapheresis) of greater than 500 mL within 90 days prior to the first dose of study drug.~* Patients with a known immunodeficiency disorder. Have a history of a major organ transplant or hematopoietic stem cell/marrow transplant.~* Patients with infections requiring treatment or hospitalization within 14 days prior to the Screening Visit, parenteral antimicrobial therapy within 60 days prior to the Screening Visit, infected joint prosthesis; history of herpes zoster, active herpes simplex, or herpes simplex on suppressive therapy.~* Patient has a chronic hepatic disease or hepatic impairment.~* Patient has a history of Mycobacterium tuberculosis or positive interferon gamma release assay for tuberculosis (IGRA-TB) or abnormal chest X-ray (for positive IGRA-TB patients).~* Patient has a history of any lymphoproliferative disorder.~* Patient has a history of COVID-19 unless fully recovered with no sequelae for 14 days.~* Patient who had a severe course of COVID-19 (extracorporeal membrane oxygenation, mechanically ventilated).~* Patient who has recent exposure to someone who has COVID-19 symptoms or positive test result.~* Patient who has a positive reverse transcription polymerase chain reaction (RT-PCR) test for Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2).~* Patient who has clinical signs and symptoms consistent with SARS-CoV-2 infection.~* Patients may not receive any live/attenuated vaccine from 30 days prior to the Screening Visit until Day 14 Follow-up Visit.~* COVID-19 vaccine should not be given 1 week prior to the Screening Visit.~* Patients with malignancy or history of malignancy except adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. Previous treatment with total lymphoid irradiation.~* History of recurrent inflammatory joint disease other than RA or history of any other autoimmune rheumatic diseases other than Sjogren's syndrome.~* Major surgery within 30 days prior to the Screening Visit or patients with planned surgery.~* Patients who have an abnormal chest X-ray for interstitial lung disease (ILD) and/or patients with history of ILD.~* History of fainting or family history of sudden death.~* Patient has any disorder that would interfere with the absorption, distribution, metabolism or excretion of study drug.~* Patient has a history of deep vein thrombosis and/or pulmonary embolism.~* Patient has poor venous access.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): The patient will receive Dose A of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
- Cohort 2 (Type: EXPERIMENTAL): The patient will receive Dose B of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
- Cohort 3 (Type: EXPERIMENTAL): The patient will receive Dose C of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).
- Cohort 4 (Type: EXPERIMENTAL): The patient will receive Dose D of TCK-276 or matching placebo orally from Day 1 to Day 7 (once daily (QD) under fed conditions).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete